Last reviewed · How we verify

epirubicin+cisplatin+capecitabine

Dutch Colorectal Cancer Group · Phase 3 active Small molecule

epirubicin+cisplatin+capecitabine is a Small molecule drug developed by Dutch Colorectal Cancer Group. It is currently in Phase 3 development.

At a glance

Generic nameepirubicin+cisplatin+capecitabine
SponsorDutch Colorectal Cancer Group
ModalitySmall molecule
PhasePhase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about epirubicin+cisplatin+capecitabine

What is epirubicin+cisplatin+capecitabine?

epirubicin+cisplatin+capecitabine is a Small molecule drug developed by Dutch Colorectal Cancer Group.

Who makes epirubicin+cisplatin+capecitabine?

epirubicin+cisplatin+capecitabine is developed by Dutch Colorectal Cancer Group (see full Dutch Colorectal Cancer Group pipeline at /company/dutch-colorectal-cancer-group).

What development phase is epirubicin+cisplatin+capecitabine in?

epirubicin+cisplatin+capecitabine is in Phase 3.

Related